Patent Number: 6,165,506

Title: Solid dose form of nanoparticulate naproxen

Abstract: Described are solid dose nanoparticulate naproxen formulations having high rates of dissolution. The solid dose nanoparticulate naproxen formulations can comprise an alkali compound, which functions to increase the dissolution rate of the naproxen following administration. Alternatively, the solid dose nanoparticulate naproxen formulation can comprise an alkali compound and an acidic compound, which can react together to form carbon dioxide. The formed carbon dioxide can also aid in increasing the dissolution rate of the naproxen following administration. Also described are solid dose nanoparticulate naproxen formulations having a decreased concentration of a binder/disintegrant agent. Such compositions also provide an increased rate of dissolution of naproxen following administration.

Inventors: Jain; Rajeev A. (Norristown, PA), Wei; Linden (Exton, PA), Swanson; Jon (North Wales, PA)

Assignee: Elan Pharma International Ltd.

International Classification: A61K 9/46 (20060101); A61K 9/14 (20060101); A61K 9/20 (20060101); A61K 009/46 (); A61K 009/14 (); A61L 009/04 (); A01N 037/10 ()

Expiration Date: 12/26/2013